Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Haemonetics Corporation is reorganizing how it reports its business segments. The company will move from three reportable segments to two, combining the Plasma and Blood Center segments into a single Apheresis segment and renaming the Hospital segment as MedSurg.
Haemonetics will begin reporting under this new structure with the first quarter of fiscal 2027, which began on March 29, 2026. To help comparison, it has posted a supplemental presentation with recast quarterly historical revenue for fiscal years 2024, 2025 and 2026, plus a recast of previously issued fiscal 2027 revenue guidance. The company explicitly states that this presentation does not reaffirm or update its fiscal 2027 guidance; any updates will come on the first quarter fiscal 2027 earnings call.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New reportable segments: 2 segments
Previous reportable segments: 3 segments
Historical revenue recast period: Fiscal 2024–2026
+2 more
5 metrics
New reportable segments
2 segments
Apheresis and MedSurg under revised structure
Previous reportable segments
3 segments
Plasma, Blood Center, Hospital prior to change
Historical revenue recast period
Fiscal 2024–2026
Quarterly revenue recast for comparability
Guidance recast period
Fiscal 2027
Previously issued revenue guidance recast to new segments
Start of new reporting
March 29, 2026
First quarter of fiscal 2027 commenced
Key Terms
reportable segment, Regulation FD Disclosure, supplemental presentation, revenue guidance, +1 more
5 terms
reportable segment financial
"announcing changes to its reportable segment structure to better align external financial reporting"
A reportable segment is a distinct part of a company’s business that management tracks separately and for which separate financial results are published, like a company showing profit and sales for each product line or geographic region. It matters to investors because it breaks a complex business into readable pieces, letting you judge which parts drive growth, which are struggling, and where management allocates resources—similar to comparing performance across different store locations.
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure. On June 5, 2026, Haemonetics Corporation"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
supplemental presentation financial
"the Company has posted to the Investor Relations page on its website a supplemental presentation outlining the reporting changes"
revenue guidance financial
"a recast of its previously issued fiscal year 2027 revenue guidance in the new segment structure"
Revenue guidance is a public estimate a company gives of how much sales it expects to earn over an upcoming period. Think of it like a weather forecast for a business’s income: it helps investors set expectations, compare actual results against promises, and decide whether the stock is priced fairly or likely to move up or down. Clear guidance reduces uncertainty and can significantly influence investor confidence and market value.
forward-looking statements regulatory
"Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781 -848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||||
Emerging Growth Company | ||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||||||||
Item 7.01 Regulation FD Disclosure.
On June 5, 2026, Haemonetics Corporation (the "Company") issued a press release announcing changes to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Beginning with the first quarter of fiscal 2027, the previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying businesses, technologies, and markets served. In connection with this announcement, the Company has posted to the Investor Relations page on its website (www.haemonetics.com) a supplemental presentation outlining the reporting changes, including quarterly historical reconciliations from the first quarter of fiscal year 2024 through the fourth quarter of fiscal year 2026, and the company has provided a recast of its previously issued fiscal 2027 guidance in the new segment structure. The Company is not reaffirming or updating its previously issued fiscal year 2027 guidance. Updates, if any, will be provided on the Company’s first quarter fiscal year 2027 earnings call.
The foregoing information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
99.1 | Press Release issued by Haemonetics Corporation on June 5, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
| June 5, 2026 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||
| Exhibit 99.1 | ||||||||
| Investor Contacts | Media Contact | |||||||
Olga Guyette, Vice President - Investor Relations & Treasury (781) 356-9763 olga.guyette@haemonetics.com | Josh Gitelson, Sr. Director - Global Communications (781) 356-9776 josh.gitelson@haemonetics.com | |||||||
David Trenk, Sr. Manager - Investor Relations (203) 733-4987 david.trenk@haemonetics.com | ||||||||
Haemonetics Updates Financial Reporting Segments
BOSTON, MA, June 5, 2026 — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two. The previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying businesses, technologies, and markets served.
Consistent with prior practice, Haemonetics expects to continue providing additional supplemental revenue disclosure in its earnings materials. The Apheresis segment will include supplemental disclosure for Plasma and Other, while the MedSurg segment will continue to include Blood Management Technologies and Interventional Technologies.
Haemonetics will begin reporting financial results under its new reportable segment structure with the first quarter of fiscal year 2027, which commenced on March 29, 2026. To facilitate comparability, the Company has posted a supplemental presentation containing recast quarterly historical revenue for fiscal years 2024, 2025, and 2026, as well as a recast of its previously issued fiscal year 2027 revenue guidance to align historical and guidance disclosures with the new reportable segment structure. The supplemental presentation is not a reaffirmation or update of the Company’s previously issued fiscal year 2027 guidance. Updates, if any, will be provided on the Company’s first quarter fiscal year 2027 earnings call.
The supplemental presentation is available on the Company's Investor Relations website which may be accessed at https://haemonetics.gcs-web.com/static-files/329078b2-08fa-45a4-ba29-f069a3e18ec3.
About Haemonetics
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) the change in the Company’s reportable segments, and prospective supplemental disclosures within this framework; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company’s ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company’s ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
FAQ
What reporting segment changes did Haemonetics (HAE) announce in this 8-K?
Haemonetics will shift from three reportable segments to two. Plasma and Blood Center are being combined into a new Apheresis segment, while the Hospital segment will be renamed MedSurg, aligning reporting with how management runs the business and allocates resources.
When will Haemonetics (HAE) start using its new segment structure?
Haemonetics will begin reporting results under the new segment structure in the first quarter of fiscal 2027. That fiscal quarter commenced on March 29, 2026, so upcoming financial disclosures from that period will use the Apheresis and MedSurg segments.
How is Haemonetics (HAE) helping investors compare historical results under the new segments?
Haemonetics posted a supplemental presentation on its Investor Relations website. It includes recast quarterly historical revenue for fiscal years 2024, 2025 and 2026, plus a recast of previously issued fiscal 2027 revenue guidance aligned with the new Apheresis and MedSurg segment structure.
Did Haemonetics (HAE) change or reaffirm its fiscal 2027 guidance?
Haemonetics states the supplemental presentation is not a reaffirmation or update of its previously issued fiscal 2027 guidance. The company indicates that any updates, if provided, will come on its first quarter fiscal 2027 earnings call, after reporting under the new segments.
Will Haemonetics (HAE) still provide detailed revenue disclosures by business area?
Yes. Haemonetics expects to continue giving supplemental revenue disclosures in its earnings materials. Under the new structure, Apheresis will include supplemental detail for Plasma and Other, while MedSurg will continue to include Blood Management Technologies and Interventional Technologies for additional transparency.